Glipon MF Tablet PR is a fixed-dose combination medication containing Metformin 500 mg and Teneligliptin 20 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving insulin sensitivity, thereby enhancing peripheral glucose uptake and utilization. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, leading to glucose-dependent stimulation of insulin secretion and suppression of glucagon release, contributing to improved glycemic control. This combination is beneficial for patients inadequately controlled on monotherapy or lifestyle modifications alone. Glipon MF Tablet PR provides sustained glycemic regulation with a favorable safety profile, minimizing the risk of hypoglycemia when used appropriately. It is recommended to be administered orally, usually twice daily, with meals to enhance absorption and reduce gastrointestinal side effects commonly associated with Metformin. Regular monitoring of blood glucose levels, renal function, and hepatic parameters is advised during therapy. Caution is warranted in patients with renal impairment, hepatic dysfunction, or cardiovascular disease. Glipon MF Tablet PR should be used as part of a comprehensive diabetes management plan including diet, exercise, and weight control to optimize therapeutic outcomes.